We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) has earned a consensus rating of “Buy” from the nine ...

KBC Group NV increased its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 54.4% in the 4th quarter ...

周五，Truist Securities重申了对Protagonist Therapeutics (NASDAQ: PTGX )的买入评级和60.00美元的目标价。该公司目前股价为38.78美元，市值23亿美元。分析师强调了该公司药物候选者rusfertide在治疗真性红细胞增多症（PV，一种血液癌症）方面的潜力。根据InvestingPro数据，该公司保持着优秀的财务健康状况，盈利能力指标强劲。

In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Protagonist Therapeutics (PTGX – Research Report), with a ...

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Protagonist Therapeutics (PTGX – Research ...

Protagonist Pictures is launching world sales at the EFM on Australian filmmaker Nicholas Clifford time travelling romantic ...

JMP Securities reiterated its Market Outperform rating on Protagonist Therapeutics (NASDAQ:PTGX) with a steady price target ...

周五，JMP Securities重申了对Protagonist Therapeutics (NASDAQ: PTGX ...